Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ANVS

Annovis Bio Inc

Dec 13 • 04:00PM ET

5.31

Dollar change -0.25
Percentage change -4.50	%

Healthcare • Biotechnology • USA • NYSE

Peers: BIIB ACAD AXSM SAVA NBIX AVXL NERV PRTA PRQR RNA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.85	Insider Own	20.40%	Shs Outstand	13.28M	Perf Week	-11.50%
Market Cap	69.97M	Forward P/E	-	EPS next Y	-1.87	Insider Trans	0.00%	Shs Float	10.98M	Perf Month	-28.34%
Income	-40.94M	PEG	-	EPS next Q	-0.32	Inst Own	8.93%	Short Float	11.95%	Perf Quarter	-33.79%
Sales	0.00M	P/S	-	EPS this Y	69.40%	Inst Trans	19.41%	Short Ratio	4.94	Perf Half Y	-9.23%
Book/sh	0.53	P/B	9.99	EPS next Y	1.71%	ROA	-333.05%	Short Interest	1.31M	Perf Year	-47.43%
Cash/sh	0.96	P/C	5.54	EPS next 5Y	-	ROE	-596.70%	52W Range	4.53 - 22.49	Perf YTD	-71.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-126.41%	ROI	-579.57%	52W High	-76.39%	Beta	1.60
Dividend TTM	-	Quick Ratio	2.66	Sales past 5Y	0.00%	Gross Margin	-	52W Low	17.22%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	2.66	EPS Y/Y TTM	9.74%	Oper. Margin	-	RSI (14)	32.09	Volatility	10.28% 8.40%
Employees	6	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	40.17
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	40.35%	Payout	-	Rel Volume	1.15	Prev Close	5.56
Sales Surprise	-	EPS Surprise	-42.04%	Sales Q/Q	-	Earnings	Nov 11 BMO	Avg Volume	265.63K	Price	5.31
SMA20	-16.31%	SMA50	-31.09%	SMA200	-38.24%	Trades		Volume	306,243	Change	-4.50%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-25-24	Upgrade	Maxim Group	Hold → Buy	$25
Dec-29-23	Initiated	Canaccord Genuity	Buy	$36
Jul-07-21	Reiterated	Maxim Group	Buy	$45 → $150

Dec-05-24 08:30AM	Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace (GlobeNewswire)
Dec-04-24 02:21PM	Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace (PR Newswire) -6.42%
Nov-25-24 08:00AM	Annovis to Host Year-End Investor Webcast on December 11, 2024 (GlobeNewswire) +6.32%
Nov-12-24 08:00AM	Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Nov-11-24 08:00AM	Annovis Bio Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -6.25%
08:00AM	Loading…
Nov-07-24 08:00AM	Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist (GlobeNewswire)
Oct-31-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio (GlobeNewswire)
Oct-22-24 08:00AM	Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 (GlobeNewswire)
Oct-17-24 10:52AM	Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug (GuruFocus.com) -5.25%
Oct-15-24 08:00AM	FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs (GlobeNewswire) +6.26%
Oct-03-24 08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
08:30AM	Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases (GlobeNewswire)
Oct-02-24 08:30AM	Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations (GlobeNewswire) +5.42%
Sep-30-24 08:00AM	Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra (GlobeNewswire)
Sep-05-24 08:00AM	Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.76%
07:00AM	Loading…
Aug-15-24 07:00AM	Annovis Bio Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) +14.05%
Aug-06-24 09:00AM	Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities (GlobeNewswire)
08:30AM	Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 (GlobeNewswire)
08:00AM	Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist (GlobeNewswire)
Aug-05-24 08:00AM	IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024 (GlobeNewswire)
Jul-24-24 08:00AM	Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap (GlobeNewswire)
Jul-16-24 08:00AM	Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap (GlobeNewswire)
Jul-09-24 08:00AM	Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team (GlobeNewswire) -5.76%
Jul-03-24 12:53PM	Annovis stock swells after Phase III Parkinsons subgroup success (Clinical Trials Arena) -12.93%
12:21PM	Annovis Bio shares dip on phase III Parkinson's trial data (Yahoo Finance Video)
09:10AM	Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study (Zacks)
Jul-02-24 04:45PM	Why Did Annovis Bio (ANVS) Stock Close Up 80% Today? (InvestorPlace) +76.09%
08:00AM	Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap (GlobeNewswire)
Jun-27-24 08:00AM	Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap (GlobeNewswire)
Jun-26-24 08:00AM	Annovis Bio Files Patent for New Composition of Matter for Buntanetap (GlobeNewswire)
08:00AM	Loading…
Jun-25-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data (GlobeNewswire) -8.70%
Jun-18-24 08:00AM	Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference 2024 (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE) -5.81%
Jun-11-24 08:00AM	Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients (GlobeNewswire)
Jun-05-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast (GlobeNewswire)
May-28-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet (Zacks) -8.78%
May-21-24 07:30AM	Annovis Announces New Publication in a Peer-Reviewed Journal (GlobeNewswire) -5.94%
May-13-24 01:53PM	ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024 (InvestorPlace) +15.51%
07:30AM	Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease (GlobeNewswire) +25.10%
May-06-24 07:30AM	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders (GlobeNewswire)
Apr-30-24 10:17AM	Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating (MT Newswires) -23.49%
Apr-29-24 02:54PM	Top Midday Decliners (MT Newswires) -59.58%
12:12PM	Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study (MT Newswires)
10:51AM	UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study (Reuters)
10:20AM	CORRECTED- Annovis Bio fails to meet main goal of mid-stage Alzheimer's treatment trial (Reuters)
10:10AM	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease (GlobeNewswire)
Apr-24-24 09:55AM	Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade (Zacks) +7.24%
Apr-08-24 09:55AM	Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-02-24 12:53PM	ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023 (InvestorPlace) -6.52%
07:30AM	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 08:00AM	Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans (GlobeNewswire)
Mar-21-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet (Zacks) +6.58%
Mar-20-24 07:30AM	Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire) +24.44%
Mar-18-24 08:52AM	Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock? (Zacks)
Mar-06-24 03:33PM	Sell Signal: 3 Stocks to Unload Before the Bubble Bursts (InvestorPlace)
Feb-27-24 08:00AM	Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024 (GlobeNewswire) +10.37%
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey) -10.76%
Feb-14-24 07:30AM	Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire)
Feb-12-24 04:06PM	3 Growth Stocks to Sell in February Before They Bottom (InvestorPlace) -5.10%
Jan-30-24 08:00AM	Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio (GlobeNewswire) -5.54%
Jan-24-24 08:00AM	Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement (GlobeNewswire) -21.91%
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey) +5.12% +28.05%
Dec-11-23 01:00PM	Annovis Bio to Participate in the 139th Yale CEO Summit (GlobeNewswire) -8.75%
Dec-05-23 07:30AM	Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease (GlobeNewswire)
Dec-01-23 11:12AM	Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why (Zacks)
07:30AM	Annovis Bio Appoints Andrew Walsh as Vice President Finance (GlobeNewswire)
Nov-27-23 07:30AM	Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections (GlobeNewswire) +13.69%
Nov-08-23 05:00PM	Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:30AM	Annovis Bio Measures Novel Biomarkers in Plasma of Parkinsons Patients (Business Wire)
Oct-31-23 08:00AM	Annovis Bio Announces Pricing of $7.5 Million Public Offering (Business Wire) -18.90%
Oct-30-23 04:48PM	Annovis Bio Announces Launch of Proposed Public Offering (Business Wire)
04:42PM	Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimers Disease Patients From the Independent Data and Safety Monitoring Board (DSMB) (Business Wire)
Oct-24-23 09:13AM	Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -7.31%
Oct-16-23 10:47AM	CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer (Zacks)
Oct-13-23 12:42PM	Annovis (ANVS) AD Study to Continue as Planned, Shares Rise (Zacks) -6.54%
Oct-12-23 11:29AM	Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study (Zacks) +9.22%
11:10AM	PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data (Zacks)
08:02AM	Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study (GlobeNewswire)
Oct-11-23 09:24AM	Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update (Zacks)
Oct-10-23 10:24AM	Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro (Zacks)
Oct-09-23 09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks) -7.26%
08:52AM	Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion (Zacks)
Oct-06-23 12:03PM	Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study (Zacks)
07:30AM	Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin (Zacks)
Oct-04-23 11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
09:32AM	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce (Zacks)
09:27AM	Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies (Zacks)
Oct-03-23 10:45AM	Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine (Zacks)
09:43AM	Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH (Zacks)
09:11AM	NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up (Zacks)
Sep-29-23 12:32PM	Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug (Zacks)
Sep-25-23 12:06PM	Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies (Zacks)
12:04PM	FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease (Zacks)
Sep-22-23 12:00PM	Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study (Zacks) -5.36%
11:57AM	Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze (Zacks)
07:57AM	Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC (Zacks)
Sep-21-23 01:23PM	Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab (Zacks)
09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANVS

Annovis Bio Inc

Upgrade your FINVIZ experience